The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
COMPARISON OF RIFAMPICIN WITH PHENOBARBITONE FOR TREATMENT OF PRURITUS IN BILIARY CIRRHOSIS
Abstract
The anti-pruritic effects of rifampicin (10 mg/kg) and phenobarbitone (3 mg/kg) were assessed in 22 patients with primary biliary cirrhosis in a crossover randomised clinical trial. Each agent was given for 14 days, with a 30-day washout period between treatments. 21 patients completed the course of rifampicin and 18 that of phenobarbitone; rifampicin was withdrawn from 1 patient when anaemia and renal failure developed, whereas 3 patients stopped taking phenobarbitone because of a rash and the 4th merely refused the drug. Rifampicin had a greater anti-pruritic effect than phenobarbitone. The symptom improved in 19 patients taking rifampicin and in 8 taking phenobarbitone, the degree of improvement being greater with rifampicin than with phenobarbitone. Pruritus disappeared in 9 patients receiving rifampicin, and three of them were free of itch when switching over to phenobarbitone. Both drugs were equally effective in inducing hepatic microsomal function but rifampicin has the additional effect of reducing cholestasis. Its anti-pruritic effect should be tested in long-term clinical trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several prospective randomised placebo-controlled trials have shown rifampicin to be effective in the management of cholestatic pruritus.182–185”
From The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines (2018) · cites this paper as [183]
Citations
Cites
Snedecor, G. W., Cochran, W. G., & STOUT, B. B. (1939) · Soil Science · doi:10.1097/00010694-193902000-00006 · Cited by 19,423
Statistical methods in medical research
Menduke, H. (1972) · Journal of the Franklin Institute · doi:10.1016/0016-0032(72)90050-6 · Cited by 1,271
IS URSODEOXYCHOLIC ACID AN EFFECTIVE TREATMENT FOR PRIMARY BILIARY CIRRHOSIS?
Poupon, R. Y., Poupon, R., Calmus, Y., Chrétien, Y., Ballet, F., & Darnis, F. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91610-2 · Cited by 534
The presentation and diagnosis of 100 patients with primary biliary cirrhosis
Sherlock, S., & Scheuer, P. J. (1973) · New England Journal of Medicine · doi:10.1056/nejm197309272891306 · Cited by 504
Christensen, E., Crowe, J., Doniach, D., Pópper, H., Ranek, L., Rodés, J., Tygstrup, N., & Williams, R. L. (1980) · Gastroenterology · doi:10.1016/0016-5085(80)90571-5 · Cited by 271
Self-citationTreatment of pruritus of primary biliary cirrhosis with rifampin
Podesta, A., Lopez, P., Terg, R., Villamil, F., Flores, D., Mastai, R., Udaondo, C. B., & Companc, J. P. (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01300759 · Cited by 267
Treatment of pruritus in primary biliary cirrhosis with rifampin
Ghent, C. N., & Carruthers, S. G. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90442-8 · Cited by 257
Lindenborn-Fotinos, J., Baum, H., & Berg, P. A. (1985) · Hepatology · doi:10.1002/hep.1840050510 · Cited by 161
Relief of the Pruritus of Jaundice with a Bile-Acid Sequestering Resin
Carey, J. B. (1961) · JAMA · doi:10.1001/jama.1961.03040180034008 · Cited by 134
Phenobarbital Effects in Cholestatic Liver Disease
BLOOMER, J. R., & BOYER, J. L. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-82-3-310 · Cited by 120
Research works printed but not linked: 2
- Pérez-Ayuso, 1980, Effect of phenobarbital treatment on pruritus and hepatic excretory function in primary biliary cirrhosis, Gastroenterology, 79, 1119
- Quintero, 1986, Utilidad del recambio plasmático intermitente en la cirrosis biliar primaria, Gastroenterol Hepatol, 9, 329
Cited by
Sorted by citations
Items 201–227 of 227
Primary Biliary Cholangitis: Its Science and Practice
Wang, L., Bowlus, C. L., Wang, F., & Gershwin, M. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-50168-0_8 · Cited by 1
Parés, A. R., & Caballería, L. (2000) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(00)70089-8 · Cited by 1
Self-citationDrug therapy of primary biliary diseases: classical and modern strategies
Schlichting, J., & Leuschner, U. (2001) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2001.tb00144.x · Cited by 1
Pirschel, W., & Kremer, A. E. (2016) · Springer eBooks · doi:10.1007/978-3-319-33142-3_34 · Cited by 1
Pruritus in Patients with Hepatobiliary Diseases
Kremer, A. E., Elferink, R. P. J. O., & Beuers, U. H. (2009) · Springer eBooks · doi:10.1007/978-1-84882-322-8_28
Orphan drugs in development for primary biliary cirrhosis: challenges and progress
Lindor, K. D., Ali, A. H., & Byrne, T. (2015) · Orphan Drugs Research and Reviews · doi:10.2147/odrr.s69477
The pruritus of cholestasis: behavioral studies shed light on its pathogenesis
Bergasa, N. V., & Jones, E. A. (1998) · Springer eBooks · doi:10.1007/978-94-011-4884-9_13
Behandlung der chronischen Cholestase im Kindesalter
Álvarez, F. (2008) · Annales Nestlé (Deutsche Aufl ) · doi:10.1159/000240394
Tratamientos de la colestasis crónica en niños
Álvarez, F. (2008) · Annales Nestlé (Ed española) · doi:10.1159/000193190
Traitements de la cholestase chronique chez l’enfant
Álvarez, F. (2008) · Annales Nestlé (Ed française) · doi:10.1159/000207605
Non-PBC, Non-PSC autoimmune cholangiopathy
Mayo, M. J. (2000) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-000-0005-z
Parés, A. R. (2016) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2016.05.003
Self-citationCoskey, R. J. (1990) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(08)81238-8
Mechanisms of bile acid inhibition of bile acid synthesis
Chiang, J. Y. L., Li, T., Spalding-Yoder, B., & Signore, S. D. (2005) · Springer eBooks · doi:10.1007/1-4020-2913-6_7
Failure of Health Care Professionals to Interpret Fecal Occult Blood Tests
Macía, M., Selinger, A., Norman, S. E., & Dominitz, J. A. (2003)
Autoimmune Liver Diseases: Primary Biliary Cholangitis
Ali, A. H., Carey, E. J., & Lindor, K. D. (2016) · Springer eBooks · doi:10.1007/978-3-319-30103-7_16
ABC Transporters Involved in Cholestasis
Cuperus, F. J. C., Gautherot, J., Halilbasic, E., Claudel, T., & Trauner, M. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527679430.ch6
Itching as the onset of pain (part 2)
Kushnir, V., Dmytrenko, S. V., Katilov, O., & Kushnir, N. (2020) · Pain medicine · doi:10.31636/pmjua.v5i1.3
Marschall, H., Wagner, M., Zollner, G., Fickert, P., Gumhold, J., Silbert, D., Diczfalusy, U., Benthin, L., Grundström, R., Gustafsson, U. O., et al. (2007) · Springer eBooks · doi:10.1007/1-4020-2913-6_28
Karlsen, T. H., Boberg, K. M., & Schrumpf, E. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6252-0_31
Weißhaar, E., & Yosipovitch, G. (2014) · Wiley eBooks · doi:10.1002/9781118357606.ch71
GREAVES, M. (2004) · doi:10.1002/9780470750520.ch16
Supplementary Figure 1 from Rifampicin as an Oral Angiogenesis Inhibitor Targeting Hepatic Cancers
Shichiri, M., Fukai, N., Kono, Y., & Tanaka, Y. (2023) · doi:10.1158/0008-5472.22377888
Pruritus, Prurigo and Lichen Simplex
Ständer, S., & Yosipovitch, G. (2024) · Wiley eBooks · doi:10.1002/9781119709268.rook081 · Cited by 1
Evaluation and management of primary sclerosing cholangitis patients awaiting liver transplantation
Frolkis, A. D., Nayagam, J. S., Parente, A., Seager, M. J., Sadler, M. D., Montaño‐Loza, A. J., & Joshi, D. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101748
Heathcote, J. (1992) · Springer eBooks · doi:10.1007/978-1-4615-3314-6_15
Austrian Society of Gastroenterology and Hepatology (ÖGGH) consensus on primary biliary cholangitis
Halilbasic, E., Tatscher, E., Aigner, E., Burghart, L., Graziadei, I. W., Hametner‐Schreil, S., Hofer, B., Hofer, H., Maieron, A., Mandorfer, M., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02798-6
Metadata
- Authors
- Bachs, L., Elena, M., Parés, A., Piera, C., & Rodés, J.
- Affiliations
- Hospital Clínic de Barcelona (ES)
- Universitat de Barcelona (ES)
- ORCID
- Parés, Albert
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 1989-03
- Volume
- 333
- Issue
- 8638
- Pages
- 574-576
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2088682754
- Cited by
- 231
- References
- 23
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 8 · 2023: 8 · 2022: 6 · 2021: 4 · 2020: 4 · 2019: 6 · 2018: 9 · 2017: 6 · 2016: 8 · 2015: 9 · 2014: 10 · 2013: 4 · 2012: 3
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- rifampicin, phenobarbital, pruritus, primary biliary cirrhosis, antipruritic effect, cholestasis, drug-induced liver injury, anemia, renal failure
- MeSH terms
- Adult, Cholestasis, Clinical Trials as Topic, Drug Administration Schedule, Female, Humans, Liver Cirrhosis, Biliary, Microsomes, Liver, Middle Aged, Phenobarbital, Pruritus, Random Allocation, Rifampin, Severity of Illness Index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
